Russia Plans to Complete Domestic MRI Scanner Development by 2027

On August 1, Russian Prime Minister Mikhail Mishustin stated that Russia should complete the development of a domestically produced MRI scanner by 2027. Mishustin learned about the relevant progress during his visit to the Consultative Diagnostic Center in the Republic of Tyva. While inspecting the MRI equipment installed at the center, he asked Russian Health Minister Mikhail Murashko about the development of domestic devices. Murashko stated that the research and development work is being carried out by Rosatom, and noted that the device is expected to be completed next year. Mishustin then expressed hope that Russia would have its own domestically developed MRI scanner next year. If the device is completed as planned, it will be used in the field of medical imaging diagnostics.

2026-08-05

US Intermountain Health Opens New Outpatient Clinic in Las Vegas, Equipped with PET/CT and Linear Accelerator

Intermountain Health, headquartered in Salt Lake City, recently opened a new outpatient clinic in southwest Las Vegas. Named Badura Clinic, the facility spans approximately 90,000 square feet and is located in the Spring Valley area, marking the health system's first new construction project in Nevada. The three-story Badura Clinic officially opened following a ribbon-cutting ceremony and community open house on July 30. The clinic consolidates primary care and select specialty services previously dispersed across multiple locations in the Las Vegas Valley, offering more centralized medical care for children, adults, and senior patients. According to the introduction, the clinic's services include adult and...

2026-08-05

ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...

2026-08-05

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

Guangzhou Taihe Proton Therapy Center Surpasses 1,000 Patients Treated

Since the ProBeam proton radiotherapy system at the Proton Therapy Center of Guangzhou Taihe Cancer Hospital was officially put into clinical use in December 2024, the center has provided proton radiotherapy services to more than 1,000 patients within 19 months, with consecutive single-day treatment volumes exceeding 100 patient sessions. According to information released by the hospital, compared with the time taken by some internationally comparable proton centers to complete 1,000 clinical cases, Guangzhou Taihe took 19 months. Relevant comparisons include: Emory Proton Therapy Center in the United States took 2 years to complete 1,000 cases after launching in December 2018; MIBS Proton Therapy Center in Russia took approximately 2 years after trial operation began in September 2017; University College London Hospitals Proton Centre in the United Kingdom took nearly 4 years after launching in December 2021; Tata Memorial Centre in Mumbai, India, took nearly 3 years after launching in 2023; and the Proton Centre at the National Cancer Centre Singapore took 26 months to complete 500 cases after launching in June 2023.

2026-08-04

Enzychem Lifesciences Signs MOU with Korea Institute of Radiological & Medical Sciences to Jointly Develop Radiation-Induced Dermatitis Treatment

Enzychem Lifesciences announced on August 4 that it has signed a Memorandum of Understanding (MOU) with the Korea Institute of Radiological & Medical Sciences (KIRAMS) for joint research on a treatment for radiation-induced dermatitis. Based on their respective research capabilities and expertise, the two parties will explore the feasibility of developing a treatment for radiation-induced dermatitis and advance joint new drug research. Radiation-induced dermatitis is one of the most common treatment-related side effects in cancer patients undergoing radiation therapy, manifesting as skin erythema, pain, itching, and peeling. In severe cases, it can delay or interrupt radiotherapy schedules, not only reducing patients' quality of life but also negatively affecting the treatment process. The treatment has recently...

2026-08-04

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

Two Joint Laboratories for Radiation Injury Treatment under the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Inaugurated in Shanghai and Wuxi

From July 30 to 31, Zhou Jiaxi, Director of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Liu Qiang, Deputy Director, Su Xu, Distinguished Professor, along with relevant heads from the National Nuclear Radiation Medical Treatment Base (Tianjin), the Science and Technology Department, and the Industry Department, successively visited Shanghai Pulmonary Hospital and the Affiliated Hospital of Jiangnan University for cooperation exchanges, and jointly inaugurated the two joint laboratories for radiation injury treatment. On the afternoon of July 30, the plaque presentation ceremony for the joint laboratory between the Institute of Radiation Medicine and Shanghai Pulmonary Hospital was held in Shanghai. Chen Chang, Deputy Secretary of the Party Committee and President of Shanghai Pulmonary Hospital, Liu Haipeng, Vice President, and heads of relevant departments attended the event. Zhou Jiaxi stated that the co-establishment of the joint laboratory is a...

2026-08-04

Zhongji Flash e-Flash 200A Enters Innovative Medical Device Special Review Program

Recently, the public notice period for the review results of applications for the Innovative Medical Device Special Review Program by the Center for Medical Device Evaluation of the National Medical Products Administration has concluded. The ultra-high dose rate electron beam radiotherapy system (e-Flash 200A), independently developed by Zhongji Flash Medical Technology Co., Ltd., has officially entered the Innovative Medical Device Special Review Program. According to reports, the e-Flash 200A is China's first ultra-high dose rate electron beam FLASH radiotherapy device and had previously been included in the "Global New" green channel. Its entry into the Innovative Medical Device Special Review Program signifies further recognition of the product's technological innovation and clinical application value. The system is designed for superficial tumor radiothe...

2026-08-04

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

United Imaging Healthcare's New-Generation Digital PET/CT "uMI Panvivo" Enters Clinical Use in Japan

August 3 news, United Imaging Healthcare Japan Co., Ltd. announced that the first unit in Japan of its new-generation digital PET/CT scanner uMI Panvivo has been put into clinical use at Saitama Central Clinic, located in Omiya-ku, Saitama City. Saitama Central Clinic is a medical institution specializing in diagnostic imaging. Since its opening in 2009, the clinic has continuously conducted comprehensive cancer screening centered on PET/CT scans, and provides FDG-PET cancer examination services based on the needs of local medical institutions, with an annual PET/CT examination volume ranking among the highest in Japan. With the introduction of uMI Panvivo, the clinic expects to further shorten examination time and enhance image quality on the basis of its existing high-precision diagnostic imaging...

2026-08-03

South Korea's Deepnoid Signs M4CXR Supply Contract with Pusan National University Hospital

On August 3, Deepnoid announced the signing of a supply contract for M4CXR with Pusan National University Hospital. M4CXR is a generative AI-based preliminary report generation solution for chest X-rays that generates preliminary reports during chest X-ray examinations to assist medical staff in image interpretation. This is the first supply agreement signed after M4CXR received approval from the Ministry of Food and Drug Safety of South Korea for market release as a digital medical device. According to the introduction, the system is expected to improve the efficiency of chest X-ray reading and provide clinical support for the early detection of lung diseases and suspected cancerous lesions. This collaboration is also part of the AI clinical system support project for regional responsible medical institutions under the Ministry of Health and Welfare of South Korea...

2026-08-03

Busan Gijang Southeast Radiation Medical Science Industrial Complex Simultaneously Advances Proton and Heavy Ion Therapy Centers

Within the Southeast Atomic Energy Medical Institute (Southeast Atomic Energy Medical Institute) in Gijang-gun, Busan, the proton therapy center and heavy ion therapy center projects are being advanced simultaneously, expected to form an integrated cancer treatment hub, alleviate medical concentration in the capital region, and attract patients from other regions and overseas. Busan's first proton accelerator project can also be used for industrial purposes, benefiting regional high-tech industries and investment attraction. According to Busan City and the Busan Institute of Science and Technology Advancement (BISTEP) on August 2, the Southeast Proton Therapy Center construction project will officially break ground in the second half of this year; BISTEP recently completed a commissioned study on the establishment strategy and implementation plan for the Southeast Proton Therapy Center (executed by the Southeast Atomic Energy Medical Institute) (Southeast...

2026-08-03

The Institute of High Energy Physics of the Chinese Academy of Sciences Successfully Held the Fourth "1+1" Youth Forum on Nuclear and Particle Physics — Frontier Technologies Empowering Nuclear Medicine Diagnosis and Treatment

On July 25, 2026, the fourth "1+1" Youth Forum on Nuclear and Particle Physics (hereinafter referred to as the "1+1 Forum") was successfully held at the Institute of High Energy Physics of the Chinese Academy of Sciences (hereinafter referred to as IHEP). Themed "Frontier Technologies Empowering Nuclear Medicine Diagnosis and Treatment," the forum was organized by the Youth Working Committee of the Beijing Nuclear Society and the IHEP Group of the Youth Innovation Promotion Association of the Chinese Academy of Sciences, co-organized by the Institute of High Energy Physics of the Chinese Academy of Sciences and the School of Nuclear Science and Technology of the University of Chinese Academy of Sciences, and hosted by the R&D Center for Nuclear Technology (Nuclear Detection and Nuclear Imaging) of the China Atomic Energy Authority and the Beijing Engineering Research Center for Radiation Imaging Technology and Equipment. The 1+1 Forum has always adhered to the principle of organically combining demand with technology, academia with science popularization...

2026-08-03

Bolivia Advances Legislative Process for Peaceful Nuclear Technology Applications

EL ALTO, Bolivia, July 29 - The Bolivian Nuclear Energy Agency (ABEN) recently held working exchanges with relevant committees of the Plurinational Legislative Assembly to discuss the reactivation of related legislative agendas, focusing on the continued advancement of Bolivia's nuclear energy program and peaceful nuclear technology application projects. René Soria Sausedo, Executive Director of ABEN, stated that as the primary operating entity of Bolivia's nuclear program, ABEN bears the responsibility of driving the implementation of peaceful nuclear technology application projects. These efforts require modern legal instruments to define institutional mandates, technical standards, and the fundamental legal framework for project development. The parliamentary delegation, led by the President of the International Policy and Migration Protection Committee, visited ABEN facilities...

2026-08-03

U.S. Department of Energy Highlights Progress in Legacy Waste Cleanup and Medical Isotope R&D

Recently, senior officials from the U.S. Department of Energy attended an event hosted by the U.S. House Nuclear Cleanup Caucus, presenting the application progress of legacy nuclear waste cleanup efforts in medical isotope R&D and future energy technologies. The event, themed "DOE's Isotope Mission: Legacy Cleanup Saves Lives, Empowers America's Future," focused on how nuclear cleanup missions align with isotope production and medical research. DOE's Under Secretary for Science Dario Gil, along with Oak Ridge National Laboratory Environmental Management Office Manager Eric Olds and Savannah River Operations Office Manager Edwin DeShon, jointly attended the event. DeShon...

2026-08-03

US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...

2026-08-03

Xinjiang's First Domestically Developed SPECT/CT Put into Operation at the First Affiliated Hospital of Shihezi University

Recently, the mid-term summary meeting of the National Key R&D Program project "Research on Application Solutions for Domestically Developed Dual-Head Single-Photon Imaging Equipment (SPECT)" under the 14th Five-Year Plan, along with the SPECT/CT commissioning ceremony and academic seminar, was held at the First Affiliated Hospital of Shihezi University. The Insight four-dimensional quantitative SPECT/CT from永新医疗 (Yongxin Medical) was officially installed in Xinjiang, becoming the first domestically developed SPECT/CT system put into clinical use in the region. A representative from the First Affiliated Hospital of Shihezi University stated that the commissioning of the domestically developed SPECT/CT will help the hospital improve its precision diagnosis and treatment system in northern Xinjiang and enhance regional nuclear medicine service capabilities. Experts attending the meeting noted that the deployment of this system in clinical practice will help explore the standardized application pathways of SPECT/CT in primary hospitals and accumulate clinical experience in the use of nuclear medicine imaging equipment in western China.

2026-08-03

Kangbuk Samsung Hospital in South Korea Validates Precision of New-Generation Surface-Guided Radiation Therapy System

The research team from the Department of Radiation Oncology at Kangbuk Samsung Hospital in South Korea announced on July 31 that they have completed validation of the geometric accuracy and respiratory tracking performance of a new-generation surface-guided radiation therapy system. The research findings have been published in the latest issue of the international academic journal *Radiation Physics and Chemistry*. In breast cancer radiotherapy, the deep inspiration breath-hold technique is commonly used in clinical practice to reduce radiation exposure to the heart and lungs. Traditional procedures typically require tattoo marks or drawn guide lines on the patient's skin surface, along with wearing sensors to monitor respiratory motion, which somewhat compromises treatment convenience and patient comfort. The new-generation surface-guided radiation therapy system validated in this study utilizes 3D stereoscopic cameras and thermal imaging technology...

2026-08-02